SUBSCRIBE
SUBSCRIBE
News   Drug Development

Novartis AG/Incyte Corporation Drug Said to Ease Blood-Cancer Symptoms

September 16, 2010 | 
1 min read
NEW YORK, Sept 15 (Reuters) - An experimental Novartis AG (NOVN.VX) medicine in an early-stage trial provided marked relief of symptoms to patients with a rare life-threatening blood cancer called myelofibrosis, the drugmaker said on Wednesday.
Clinical research Phase I
Incyte Novartis
MORE ON THIS TOPIC
Sep 17, 2020 Fremont / CA / USA - Novo Nordisk headquarters in Silicon Valley; Novo Nordisk A/S is a Danish multinational pharmaceutical company
Cardiovascular disease
Novo’s Wegovy Cuts Cardio Risk by 57% Versus Tirzepatide
September 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Indianapolis, U.S. - April 16, 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals VII
Obesity
Lilly Ends Two Mid-Stage Trials for Second Obesity Asset
September 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Allschwil, Switzerland - 09. May 2022: The modern architecture of business center of Johnson and Johnson, which is a world famous company for pharmaceuticals and biotechnology.
Immunology and inflammation
J&J Ends Rheumatoid Arthritis Program After Disappointing Mid-Stage Data
August 29, 2025
 · 
2 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Alzheimer’s
Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test
August 28, 2025
 · 
2 min read
 · 
Annalee Armstrong